AZGP1 (Alpha-2-Glycoprotein 1, Zinc-Binding)

Spatial transcriptomics revealed significant variability in biomarker gene expression across highly heterogeneous prostate cancer tissue sections from two patients, providing proof-of-concept for its potential use in prognostic biomarker panel research. Several Oncotype DX genes were notably spatially variable, predominantly localizing to stromal regions, whilst the majority of biomarker genes from other panels exhibited non-spatial patterns. Although low-abundance genes may be impacted by current technological limitations, integrating spatial data into biomarker research holds promise for developing "spatially robust" panels to provide reliable prognostic information amidst molecular heterogeneity in prostate cancer.

In conclusion, our work elucidates a coherent epigenetic pathway wherein entinostat activates AZGP1 to inhibit HCC metastasis. These findings nominate AZGP1 as both a critical mediator and a potential biomarker for entinostat-based therapy in advanced HCC.

Furthermore, EHMT2 and TGF-β1 inhibitors suppressed tumors in immunocompetent, but not in immunodeficient mice. These findings establish EHMT2 as a suppressor of NK cell-mediated anti-tumor immunity and a promising therapeutic target.

We identified some differentially expressed genes relevant to oncogenic signaling and immunosuppressive tumor-associated macrophages. These findings provide novel insights into factors affecting prognosis in patients with residual disease after NAC for early-stage TNBC.

A high mRNA expression level of AZGP1 was associated with longer disease-free survival, whereas high mRNA expressions of ASPN, COMP, RYR2, and SFRP4 were associated with shorter disease-free survival. Prostate cancer patients with genomic alterations associated with PNI may face a higher risk of disease progression after prostatectomy, highlighting the need for further prospective studies to validate these findings.

Additionally, the levels of the phosphorylated forms of FAK, AKT, and mTOR were significantly reduced in both AGS/DDP and SGC-7901/DDP cells treated with the combination of DDP and SSD, whereas the PTEN expression level increased. Our findings highlight the importance of alternative components within the tumor microenvironment for GC therapy and identify FAK/AKT/mTOR signaling as a potential target of SSD, providing novel insights into the mechanism by which SSD improves DDP resistance in GC.

We propose a plan that includes the development of reference standards, conducting large prospective trials within biobank networks, and using artificial intelligence to discover combined proteomic signatures of the disease. These efforts aim to establish serum AZGP1 as a reliable, minimally invasive biomarker that improves early detection, prognostic stratification, and informs precision oncology.

In conclusion, EHHADH functions as an important regulator of lipid metabolism in LUSC and plays a key role in the occurrence, progression, and treatment of lung cancer. The important impact of EHHADH in lipid metabolism disorders suggests potential utility as a biomarker for diagnosis and a target for personalized treatment strategies in lung cancer.

HPV oncoproteins and high doses of arecoline are risk factors for an overexpressed ZAG protein that has an anti-apoptotic function in OSCC.

These findings underscore the pro-cancer role of taurine and proline, highlighting the Azgp1/mTOR axis as a vital, yet overlooked, pathway in lung cancer. This study not only advances our understanding but also identifies new therapeutic avenues.